Ubs Group Ag Arbutus Biopharma Corp Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Ubs Group Ag holds 774,594 shares of ABUS stock, worth $3.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

774,594

Previous 190,208 307.24%

Holding current value

$3.5 Million

Previous $587,000 498.98%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$3.08 - $4.9 $1.8 Million - $2.86 Million	584,386 Added 307.24%	774,594 $3.52 Million
Q2 2025 Aug 14, 2025	SELL	$2.88 - $3.61 $6,001 - $7,523	-2,084 Reduced 1.08%	190,208 $587,000
Q1 2025 May 13, 2025	BUY	$3.06 - $3.59 $279,338 - $327,720	91,287 Added 90.38%	192,292 $671,000
Q4 2024 Feb 14, 2025	SELL	$3.18 - $4.2 $214,233 - $282,949	-67,369 Reduced 40.01%	101,005 $330,000
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $351,652 - $513,953	112,709 Added 202.48%	168,374 $648,000

Q2 2024 Aug 13, 2024	SELL	$2.52 - $3.63 $199,478 - $287,343	-79,158 Reduced 58.71%	55,665 $172,000
Q1 2024 May 13, 2024	SELL	$2.26 - $2.92 $11,634 - $15,032	-5,148 Reduced 3.68%	134,823 $347,000
Q4 2023 Feb 09, 2024	BUY	$1.69 - $2.54 $130,726 - $196,476	77,353 Added 123.53%	139,971 $349,000
Q3 2023 Nov 09, 2023	SELL	$1.9 - $2.27 $10,543 - $12,596	-5,549 Reduced 8.14%	62,618 $127,000
Q2 2023 Aug 11, 2023	BUY	$2.24 - $3.06 $70,564 - $96,396	31,502 Added 85.92%	68,167 $156,000
Q1 2023 May 12, 2023	BUY	$2.23 - $3.1 $29,828 - $41,465	13,376 Added 57.43%	36,665 $111,000
Q4 2022 Feb 08, 2023	BUY	$1.91 - $2.85 $44,481 - $66,373	23,289 New	23,289 $54,000
Q2 2022 Aug 10, 2022	SELL	$1.98 - $3.17 $2,570 - $4,114	-1,298 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $79,400 - $130,583	-32,810 Reduced 96.19%	1,298 $4,000
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $106,075 - $157,237	34,108 New	34,108 $132,000
Q3 2021 Nov 15, 2021	SELL	$2.65 - $4.62 $165,121 - $287,872	-62,310 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$2.5 - $3.51 $27,012 - $37,925	-10,805 Reduced 14.78%	62,310 $189,000
Q1 2021 May 12, 2021	BUY	$3.14 - $4.84 $173,293 - $267,114	55,189 Added 307.87%	73,115 $244,000
Q4 2020 Feb 11, 2021	BUY	$2.76 - $4.97 $30,119 - $54,237	10,913 Added 155.61%	17,926 $64,000
Q3 2020 Nov 12, 2020	SELL	$1.75 - $6.2 $555,238 - $1.97 Million	-317,279 Reduced 97.84%	7,013 $22,000
Q2 2020 Jul 31, 2020	SELL	$0.91 - $2.36 $41,728 - $108,220	-45,856 Reduced 12.39%	324,292 $590,000
Q1 2020 May 01, 2020	BUY	$1.01 - $3.42 $128,199 - $434,100	126,930 Added 52.19%	370,148 $374,000
Q4 2019 Feb 14, 2020	BUY	$0.87 - $2.89 $49,671 - $165,001	57,094 Added 30.68%	243,218 $676,000
Q3 2019 Nov 14, 2019	BUY	$1.34 - $2.4 $26,418 - $47,316	19,715 Added 11.85%	186,124 $284,000
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $234,549 - $713,286	160,650 Added 2789.55%	166,409 $346,000
Q1 2019 May 14, 2019	BUY	$3.41 - $4.57 $3,935 - $5,273	1,154 Added 25.06%	5,759 $21,000
Q4 2018 Feb 14, 2019	BUY	$3.5 - $9.66 $11,263 - $31,085	3,218 Added 232.01%	4,605 $18,000
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $285,543 - $449,231	-36,375 Reduced 96.33%	1,387 $13,000
Q2 2018 Aug 14, 2018	SELL	$5.0 - $7.35 $21,015 - $30,892	-4,203 Reduced 10.02%	37,762 $276,000
Q1 2018 May 15, 2018	SELL	$4.4 - $6.05 $10,542 - $14,495	-2,396 Reduced 5.4%	41,965 $210,000
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $36,512 - $63,178	-8,205 Reduced 15.61%	44,361 $224,000
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $178,333 - $367,157	52,451 Added 45609.57%	52,566 $326,000
Q2 2017 Aug 14, 2017	SELL	N/A	-1,739 Reduced 93.8%	115 $0
Q1 2017 Nov 14, 2017	BUY	N/A	1,854	1,854 $6,000

Others Institutions Holding ABUS

# of Institutions

194

Shares Held

118M

Call Options Held

2.67M

Put Options Held

693K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $678M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account